Scientists_NNS have_VBP developed_VBN a_DT blood_NN test_NN that_WDT can_MD predict_VB whether_IN people_NNS with_IN depression_NN will_MD respond_VB to_TO common_JJ antidepressants_NNS ,_, a_DT discovery_NN that_WDT could_MD bring_VB in_RP a_DT new_JJ era_NN of_IN personalised_JJ treatment_NN for_IN people_NNS with_IN the_DT debilitating_VBG mental_JJ illness_NN ._.
Guided_VBN by_IN this_DT test_NN ,_, the_DT researchers_NNS said_VBD ,_, doctors_NNS should_MD in_IN future_JJ be_VB able_JJ to_TO direct_VB depressed_JJ patients_NNS with_IN a_DT certain_JJ level_NN of_IN inflammation_NN in_IN their_PRP$ blood_NN towards_IN earlier_JJR treatment_NN with_IN a_DT more_RBR potent_JJ course_NN of_IN antidepressants_NNS ,_, possibly_RB including_VBG combining_VBG two_CD medications_NNS ,_, before_IN they_PRP get_VBP worse_JJR ._.
``_`` This_DT study_NN moves_VBZ us_PRP a_DT step_NN closer_RBR to_TO providing_VBG personalised_JJ antidepressant_JJ treatment_NN at_IN the_DT earliest_JJS signs_NNS of_IN depression_NN ,_, ''_'' said_VBD Annamaria_NNP Cattaneo_NNP ,_, who_WP led_VBD the_DT work_NN at_IN King_NNP 's_POS College_NNP London_NNP 's_POS Institute_NNP of_IN Psychiatry_NNP ,_, Psychology_NNP &_CC Neuroscience_NNP -LRB-_-LRB- IoPPN_NNP -RRB-_-RRB- ._.
Depression_NN is_VBZ one_CD of_IN the_DT most_RBS common_JJ forms_NNS of_IN mental_JJ illness_NN ,_, affecting_VBG more_JJR than_IN 350_CD million_CD people_NNS worldwide_JJ ._.
It_PRP is_VBZ ranked_VBN by_IN the_DT World_NNP Health_NNP Organisation_NNP -LRB-_-LRB- WHO_WP -RRB-_-RRB- as_IN the_DT leading_VBG cause_NN of_IN disability_NN globally_RB ._.
Treatment_NNP usually_RB involves_VBZ either_CC medication_NN ,_, some_DT form_NN of_IN psychotherapy_JJ ,_, or_CC a_DT combination_NN of_IN both_DT ._.
But_CC around_IN half_DT of_IN all_DT people_NNS treated_VBN for_IN depression_NN fail_VBP to_TO get_VB better_JJR with_IN first-line_JJ antidepressants_NNS ,_, and_CC around_IN a_DT third_JJ of_IN patients_NNS are_VBP resistant_JJ to_TO all_DT available_JJ medications_NNS designed_VBN to_TO help_VB ._.
Until_IN now_RB ,_, doctors_NNS have_VBP not_RB been_VBN able_JJ to_TO establish_VB whether_IN someone_NN will_MD respond_VB to_TO an_DT antidepressant_JJ ,_, or_CC whether_IN they_PRP might_MD need_VB a_DT more_RBR aggressive_JJ treatment_NN plan_NN from_IN the_DT start_NN ._.
As_IN a_DT result_NN ,_, patients_NNS are_VBP often_RB treated_VBN with_IN a_DT trial-and-error_JJ approach_NN ,_, trying_VBG one_CD drug_NN after_IN another_DT for_IN months_NNS on_IN end_NN and_CC often_RB seeing_VBG no_DT improvement_NN in_IN their_PRP$ symptoms_NNS ._.
In_IN this_DT study_NN ,_, published_VBN on_IN Tuesday_NNP in_IN the_DT International_NNP Journal_NNP of_IN Neuropsychopharmacology_NNP ,_, Cattaneo_NNP 's_POS team_NN focused_VBD on_IN two_CD biomarkers_NNS that_WDT measure_VBP blood_NN inflammation_NN ._.
Previous_JJ studies_NNS have_VBP already_RB linked_VBN raised_VBN levels_NNS of_IN inflammation_NN with_IN a_DT poor_JJ response_NN to_TO antidepressants_NNS ._.
The_DT researchers_NNS measured_VBN the_DT two_CD markers_NNS ,_, called_VBN Macrophage_NNP Migration_NNP Inhibitory_NNP Factor_NNP -LRB-_-LRB- MIF_NNP -RRB-_-RRB- and_CC interleukin_NN -LRB-_-LRB- IL_NNP -RRB-_-RRB- -1_CD ,_, in_IN two_CD groups_NNS of_IN depressed_JJ patients_NNS before_IN or_CC after_IN they_PRP took_VBD a_DT range_NN of_IN commonly_RB prescribed_VBN antidepressants_NNS ._.
They_PRP found_VBD that_IN blood_NN readings_NNS above_IN a_DT certain_JJ threshold_NN could_MD reliably_RB predict_VB the_DT probability_NN of_IN a_DT patient_JJ responding_VBG ._.
Patients_NNS with_IN MIF_NNP and_CC IL-1_JJ levels_NNS above_IN the_DT thresholds_NNS had_VBD a_DT 100_CD %_NN chance_NN of_IN not_RB responding_VBG to_TO conventional_JJ ,_, commonly_RB prescribed_VBN antidepressants_NNS ,_, the_DT researchers_NNS found_VBD ,_, while_IN those_DT with_IN lower_JJR levels_NNS did_VBD show_VB a_DT positive_JJ treatment_NN response_NN ._.
Carmine_NNP Pariante_NNP ,_, a_DT IoPPN_NNP professor_NN who_WP worked_VBD on_IN the_DT team_NN ,_, said_VBD the_DT results_NNS point_NN to_TO a_DT <sup>_JJ ~_CD </sup>_JJ clinically-suitable_JJ approach_NN for_IN personalising_VBG antidepressant_JJ therapy_NN <sup>_NN TM_NNP </sup>_NNP ._.
